Navigation Links
Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015
Date:4/1/2015

ROCKVILLE, Md., April 1, 2015 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that clinical data supporting the development of SYN-004, the Company's candidate therapy designed to degrade certain beta-lactam intravenous (IV) antibiotics within the gastrointestinal (GI) tract and maintain the natural balance of the gut microbiome for the prevention of C. difficile infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections, has been selected for presentation during the 115th General Meeting of the American Society of Microbiology (ASM2015) in New Orleans, LA on May 30-June 1.

A second poster featuring Synthetic Biologics' data will be presented at ASM2015. These data support expanding the development of therapeutics designed to protect the microbiome from all beta-lactam antibiotics for the prevention of C. difficile infection, beyond penicillins and cephalosporins. The schedule for the two poster presentations will be as follows:

Title: Clinical Evaluation of SYN-004, an Oral Beta-Lactamase Therapy for the Prevention of Antibiotic-Induced Disruption of Intestinal Microflora
Authors: J. Sliman, J. A. Bristol, S. Hubert, O. Coughlin, J. Kokai-Kun, A. Sloan, H. Whalen, T. Roberts, M. Schlosser, S. Connelly, P. Koski, M. Kaleko; Synthetic Biologics, Inc., Rockville, MD
Date/Time: Monday, June 1, 2015, 10:45am - 12:00pm (CT)
Poster Board Number: 953

Title: Development of Therapeutic Agents that Protect the Colonic Microflora from All Beta-Lactam Antibiotics for the Prevention of Clostridium difficile Infection
Authors: S. Connelly1, T. Parsley2, P. Koski1, M. Kaleko1; 1Synthetic Biologics, Inc., Rockville, MD, 2SynPhaGen, LLC, Rockville, MD
Date/Time: Tuesday, June 2, 2015, 12:30pm - 1:45pm (CT)
Poster Board Number: 2339

"Our microbiome-focused, C. difficile preventive therapy candidate, SYN-004, continues to gain recognition and attention as this clinical program moves into Phase 2 development," stated Jeffrey Riley, Chief Executive Officer of Synthetic Biologics. "We initiated a Phase 2a clinical trial of SYN-004 in March, and anticipate initiating a Phase 2b clinical trial during the second half of this year."

The U.S. Centers for Disease Control and Prevention (CDC) has categorized C. difficile as an "urgent public health threat," and has stated the need for research to better understand the role of normal gut bacteria. SYN-004 is intended to block the unintended harmful effects of antibiotics within the GI tract and maintain the natural balance of the gut microbiome, potentially preventing the 1.1 million C. difficile infectionsi and 30,000 C. difficile-related deathsii in the United States each year. Approximately 118 million doses of IV beta-lactam antibioticsiii that could be inactivated in the GI tract by SYN-004, were administered to approximately 14 million hospitalized U.S. patients during 2012.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical-stage biotechnology company developing pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome. The Company is developing an oral biologic to protect the gut microbiome from  intravenous (IV) antibiotics for the prevention of C. difficile infection, an oral statin treatment to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS), and in collaboration with Intrexon Corporation (NYSE: XON), a monoclonal antibody combination for the treatment of Pertussis. In addition, the Company is developing a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

This release includes forward-looking statements on Synthetic Biologics' current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the intended treatment for SYN-004, continued recognition and attention of SYN-004, anticipated timing of the initiation of the Phase 2b clinical trial  and the size of the market. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Synthetic Biologics' forward-looking statements include, among others, the ability of SYN-004 to perform as expected, the results of the clinical trials and other factors described in Synthetic Biologics' report on Form 10-K for the year ended December 31, 2014 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

i This information is an estimate derived from the use of information under license from the following IMS Health Incorporated information service: CDM Hospital database for full year 2012. IMS expressly reserves all rights, including rights of copying, distribution and republication.
ii U.S. Department of Health & Human Services. Agency for Healthcare Research and Quality. January 25, 2012. http://www.ahrq.gov/news/nn/nn012512.htm Accessed: September 30, 2013.
iii This information is an estimate derived from the use of information under license from the following IMS Health Incorporated information service: CDM Hospital database for full year 2012. IMS expressly reserves all rights, including rights of copying, distribution and republication.

Logo - http://photos.prnewswire.com/prnh/20130522/MM19465LOGO


'/>"/>
SOURCE Synthetic Biologics, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. Synthetic Biologics Reports Year End 2014 Financial Results and Operational Highlights
2. Synthetic Biologics to Present at the 27th Annual ROTH Conference
3. Expanding Application Areas to Drive Growth in the Global Synthetic Biology Market, According to a New Report by Global Industry Analysts, Inc.
4. Kuros Announces Grant of US Patent for its Synthetic Hydrogel Technology
5. Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection
6. Synthetic Biology Market to HIt $5.6304 Billion by 2018 - New Research Report by MarketsandMakets
7. Bioadhesives Poised to Replace Synthetic Solutions, Finds Frost & Sullivan
8. Intrexon Announces the Appointment of Peter Emtage, Ph.D., as Vice President, Synthetic Immunology
9. Synthetic Biology Market by Tool, Technology (Bioinformatics, Nanotechnology, Gene Synthesis, Cloning & Sequencing), Application (Biofuels, Pharmaceuticals, Biomaterials, Bioremediation) - Global Forecast to 2018
10. Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets
11. Synthetic Biologics to Report Third Quarter 2014 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... -- International research firm Parks Associates announced today that ... TMA 2017 Annual Meeting , October 11 in Scottsdale, Arizona ... market and how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase ... "The residential security market has experienced continued growth, ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings announced ... by which its ProCell stem cell therapy prevents ... ischemia.  The Company, demonstrated that treatment with ProCell ... limbs saved as compared to standard bone marrow ... HGF resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... (PRWEB) , ... October 09, ... ... published on October 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s ... the gold standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) using ...
(Date:10/6/2017)... (PRWEB) , ... October 06, 2017 , ... ... entrepreneurship within the healthcare and technology sector at their fourth annual Conference where ... featuring 30 inspiring speakers and the ELEVATE pitch competition showcasing early stage digital ...
Breaking Biology Technology:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
(Date:3/29/2017)... , March 29, 2017  higi, the health ... in North America , today announced ... and the acquisition of EveryMove. The new investment and ... set of tools to transform population health activities through ... lifestyle data. higi collects and secures data ...
Breaking Biology News(10 mins):